Trial Profile
A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms MONARCH; SARIL-RA-MONARCH
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 02 Mar 2023 Results assessing disease activity after switch to Sarilumab in patients with Rheumatoid arthritis with partial response to adalimumab were published in the JCR: Journal of Clinical Rheumatology
- 02 Feb 2023 Results of two studies ( EXTEND and MONARCH OLE) assessing long-term safety and efficacy of sarilumab in rheumatoid arthritis patients, published in the Rheumatology.
- 22 Nov 2022 Results of pooled analysis from (NCT01061736, NCT02332590, NCT01709578, NCT01146652) assessing disproportionate articular pain prevalence and effects of sarilumab published in the Rheumatology